ZFIN ID: ZDB-IMAGE-090331-9
Efficacy and perdurance of rx1 and rx2 splice site-targeting MOs in embryos treated at the 1–2-cell stage (“0 hpf”) and at 44.5 hpf. The presence of large amplicons (upper row) indicates aberrant splicing. Lanes 1 and 2, embryos injected with rx1 or rx2-targeted MOs at 0 hpf and extracted at 30 hpf; lanes 3 and 4, embryos injected with the 5-mispair control MO at 0 hpf and extracted at 53 hpf; lanes 5 and 6, embryos injected with rx1 or rx2-targeted MOs at 0 hpf and extracted at 53 hpf; lanes 7 and 8, embryos injected with rx-1 or rx2-targeted MOs at 44.5 hpf and extracted at 53 hpf; lanes 9–12, embryos injected with rx1- or rx2-targeted MOs at 0 hpf (lanes 9 and 10) or at 44.5 hpf (lanes 11 and 12) and extracted at 60 hpf.
ZFIN wishes to thank the journal for permission to reproduce figures from this article.
Please note that this material may be protected by copyright.